Table 1.
Comparison of grade 3 and 4 adverse events (AEs) related to taxane treatment in studies of Asian and Western populations.
| Population | mHSPC | mHSPC | mCRPC | mCRPC | mCRPC | mCRPC |
|---|---|---|---|---|---|---|
| Study Location | Hong Kong [22] | USA (CHAARTED Study) [23] | Hong Kong [24] | UK (TAX-327 Study) [25] | Asia-Pacific * (CUP/EAP Study) [26] | Europe (CUP/EAP Study) [26] |
| Grade 3/4 Adverse Events (%) | ||||||
| Febrile neutropenia | 12.5 | 6.2 | 14.1 | 3.0 | 15.1 | 4.8 |
| Neutropenia | 40.6 | 12.1 | 47.4 | 32.0 | 27.3 | 17.1 |
| Thrombocytopenia | 0 | 0.3 | 0 | 1.0 | 1.7 | 1.0 |
| Anaemia | 3.1 | 1.3 | 10.6 | 5.0 | 12.2 | 3.1 |
| Neuropathy | 0 | 0.5 | 0 | 0 | N/A | N/A |
| Fatigue | 0 | 4.1 | 0 | 5.0 | 4.7 | 6.8 |
| Diarrhoea | 0 | 1.0 | 1.8 | 0 | 6.4 | 3.0 |
| Stomatitis | 0 | 0.5 | 1.8 | 0 | N/A | N/A |
CUP/EUP = pooled analysis of cabazitaxel compassionate use and early access programmes; mHSPC/mCRPC = metastatic hormone-sensitive/castration-resistant prostate cancer, respectively; N/A = not available. * Includes Australia, Bangladesh, Taiwan, India, Kazakhstan, South Korea, Malaysia, Philippines, Singapore and Thailand.